Recently, some concerns [1-3] have been raised about the reliability of data presented in the current paper [4], which reported results from a non-randomised phase 1/2 study of a novel vaccine from Russia. The critics of the study [4] concentrated on potential data inconsistencies [1-3] in figures and analyzed them visually (here we ignore theoretical discussions about special features of the vaccine and/or vector). However, the baseline data and results of the safety data should be considered as well.

References

1. Bucci E. “Note of concern”. In: Cattivi Scienziati (2020).
2. Lowe D. “The Russian vaccine data”. In: Science Translational Medicine (2020).
3. Bucci E. “Safety and efficacy of the Russian COVID-19 vaccine: more information needed”. The Lancet10256 (2020): e53.
4. Logunov D., et al. “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non- randomised phase 1/2 studies from Russia”. The Lancet 396.10255 (2020): 887-897.
5. Idrovo A., et al. “Performance of public health surveillance systems during the influenza A(H1N1) pandemic in the Americas: testing a new method based on Benford's Law”. Epidemiology and Infection12 (2011): 1827-1834.

Citation

Citation: Dragutin Novosela and Matija Alanovic. “Analysis of Consistency of Prime-boost Covid-19 Baseline and Safety Data". Acta Scientific Medical Sciences 4.12 (2020): 81-82.

Copyright

Copyright: © 2020 Dragutin Novosela and Matija Alanovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.